Familial Chylomicronemia Syndrome Clinical Trial
Official title:
ISIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 304801) An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
An open-label study of volanesorsen (ISIS 304801) administered subcutaneously to participants with FCS.
This is a multi-center, open-label study for FCS participants rolling over from the ISIS 304801-CS6 (NCT02211209) index study, FCS participants rolling over from the ISIS 304801-CS16 (NCT02300233) index study and Treatment-naïve group. All participants were to receive volanesorsen 300 milligrams (mg) once per week for 52 weeks. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Participants had the option of continuing dosing for an additional 52 weeks (France: up to an additional 104 weeks for a total of 156 weeks) until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week (France: 26-week) post-treatment evaluation period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04223908 -
InFocus France Epidemiological Study of Health Burden in Major Hypertriglyceridemia
|
||
| Active, not recruiting |
NCT05130450 -
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
|
Phase 3 | |
| Completed |
NCT04568434 -
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
|
Phase 3 | |
| Completed |
NCT03912181 -
Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes
|
||
| Not yet recruiting |
NCT05902598 -
A Phase 3 Study of VSA001 in Chinese Adults With Familial Chylomicronemia Syndrome
|
Phase 3 | |
| Active, not recruiting |
NCT05185843 -
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
|
Phase 3 | |
| Completed |
NCT03360747 -
Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
|
Phase 2 | |
| Completed |
NCT02211209 -
The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
|
Phase 3 | |
| Available |
NCT06360237 -
Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
|